Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 30,093,550 shares, a decrease of 11.1% from the September 28th total of 33,858,926 shares. Based on an average daily trading volume, of 4,046,366 shares, the days-to-cover ratio is presently 7.4 days. Approximately 15.0% of the shares of the company are short sold.

In other news, Director Roger H. Kimmel sold 26,074 shares of the company’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total value of $414,576.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.80% of the stock is owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Xact Kapitalforvaltning AB boosted its position in Endo International by 44.5% during the first quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock worth $174,000 after purchasing an additional 9,000 shares in the last quarter. James Investment Research Inc. lifted its position in shares of Endo International by 594.9% in the third quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock valued at $184,000 after acquiring an additional 9,370 shares in the last quarter. First Hawaiian Bank purchased a new position in shares of Endo International in the third quarter valued at approximately $358,000. United Services Automobile Association lifted its position in shares of Endo International by 16.7% in the second quarter. United Services Automobile Association now owns 41,508 shares of the company’s stock valued at $391,000 after acquiring an additional 5,933 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Endo International by 1,209.0% in the third quarter. Nisa Investment Advisors LLC now owns 26,179 shares of the company’s stock valued at $441,000 after acquiring an additional 24,179 shares in the last quarter. Institutional investors own 98.43% of the company’s stock.

A number of brokerages have recently commented on ENDP. Cantor Fitzgerald set a $12.00 target price on Endo International and gave the stock a “hold” rating in a research note on Wednesday, August 8th. Canaccord Genuity set a $13.00 target price on Endo International and gave the stock a “hold” rating in a research note on Wednesday, August 1st. ValuEngine upgraded Endo International from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 25th. BMO Capital Markets upped their target price on Endo International from $9.00 to $16.00 and gave the stock a “market perform” rating in a research note on Friday, August 10th. They noted that the move was a valuation call. Finally, Royal Bank of Canada upgraded Endo International from a “sector perform” rating to an “outperform” rating and set a $26.00 price target on the stock in a research report on Monday, August 13th. Fifteen investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.91.

Shares of ENDP stock opened at $16.30 on Monday. The company has a market cap of $3.65 billion, a price-to-earnings ratio of 4.24, a price-to-earnings-growth ratio of 1.57 and a beta of 0.70. Endo International has a 12-month low of $5.27 and a 12-month high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.54 by $0.22. The company had revenue of $714.70 million for the quarter, compared to the consensus estimate of $679.72 million. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. Endo International’s revenue for the quarter was down 18.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.93 earnings per share. As a group, equities analysts forecast that Endo International will post 2.6 EPS for the current fiscal year.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: Relative Strength Index

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.